JP2016510982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510982A5 JP2016510982A5 JP2015562104A JP2015562104A JP2016510982A5 JP 2016510982 A5 JP2016510982 A5 JP 2016510982A5 JP 2015562104 A JP2015562104 A JP 2015562104A JP 2015562104 A JP2015562104 A JP 2015562104A JP 2016510982 A5 JP2016510982 A5 JP 2016510982A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- seq
- mutation
- nucleotide
- allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 78
- 125000003729 nucleotide group Chemical group 0.000 claims description 53
- 239000002773 nucleotide Substances 0.000 claims description 50
- 230000035772 mutation Effects 0.000 claims description 43
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 102200085790 rs121913281 Human genes 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 19
- 108700028369 Alleles Proteins 0.000 claims description 18
- 102200085639 rs104886003 Human genes 0.000 claims description 13
- 102200085641 rs121913273 Human genes 0.000 claims description 13
- 102200085635 rs121913274 Human genes 0.000 claims description 13
- 102200085637 rs121913274 Human genes 0.000 claims description 13
- 102200085788 rs121913279 Human genes 0.000 claims description 13
- 102200085789 rs121913279 Human genes 0.000 claims description 13
- 102200085787 rs121913283 Human genes 0.000 claims description 13
- 102200085791 rs121913286 Human genes 0.000 claims description 13
- 102200085792 rs121913286 Human genes 0.000 claims description 13
- 102220197790 rs397517201 Human genes 0.000 claims description 13
- 102220006545 c.1035C>A Human genes 0.000 claims description 12
- 102220197894 rs121913277 Human genes 0.000 claims description 12
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 101150063858 Pik3ca gene Proteins 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- 101100190564 Homo sapiens PIK3CA gene Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000003321 amplification Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- -1 nucleoside triphosphates Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 108700026093 human PI3KCA Proteins 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000053900 human PI3KCA Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780017P | 2013-03-13 | 2013-03-13 | |
| US61/780,017 | 2013-03-13 | ||
| PCT/EP2014/054766 WO2014140061A2 (en) | 2013-03-13 | 2014-03-12 | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510982A JP2016510982A (ja) | 2016-04-14 |
| JP2016510982A5 true JP2016510982A5 (enExample) | 2018-09-06 |
| JP6453781B2 JP6453781B2 (ja) | 2019-01-16 |
Family
ID=50277211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562104A Active JP6453781B2 (ja) | 2013-03-13 | 2014-03-12 | ヒトｐｉ３ｋｃａ（ｐｉｋ３ｃａ）遺伝子変異検出のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140272961A1 (enExample) |
| EP (1) | EP2971075B1 (enExample) |
| JP (1) | JP6453781B2 (enExample) |
| CN (2) | CN105229171A (enExample) |
| CA (1) | CA2899712C (enExample) |
| ES (1) | ES2691306T3 (enExample) |
| WO (1) | WO2014140061A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| CN109913481B (zh) * | 2019-04-24 | 2020-04-03 | 无锡市第五人民医院 | PIK3CA基因g.179224821G＞A突变及其在乳腺癌辅助诊断中的应用 |
| KR102813811B1 (ko) * | 2020-03-27 | 2025-05-30 | 주식회사 젠큐릭스 | Pik3ca 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
| CN111363827A (zh) * | 2020-04-30 | 2020-07-03 | 北京和合医学诊断技术股份有限公司 | 用于检测pik3ca基因突变的引物组及其应用方法 |
| CN114410790B (zh) * | 2022-01-27 | 2024-04-12 | 湖南大学 | 一种用于检测ctDNA的生物传感检测系统及其检测方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2663248T3 (es) * | 2004-03-02 | 2018-04-11 | The Johns Hopkins University | Mutaciones del gen de PIK3CA en cánceres humanos |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| JP5624044B2 (ja) * | 2008-10-20 | 2014-11-12 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改善されたアレル−特異的増幅 |
| US20100286143A1 (en) * | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| US9238832B2 (en) * | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| EP3246332B1 (en) * | 2010-01-12 | 2019-07-10 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting pik3ca mutations |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| KR101825121B1 (ko) * | 2010-08-13 | 2018-02-06 | 주식회사 파나진 | Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｐｉｋ3ｃａ 돌연변이 검출 방법 및 키트 |
| JP6050820B2 (ja) * | 2011-09-23 | 2016-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改良された対立遺伝子特異的ｐｃｒのためのｇ−クランプの使用 |
-
2014
- 2014-03-12 WO PCT/EP2014/054766 patent/WO2014140061A2/en not_active Ceased
- 2014-03-12 EP EP14709926.1A patent/EP2971075B1/en active Active
- 2014-03-12 CN CN201480013282.7A patent/CN105229171A/zh active Pending
- 2014-03-12 ES ES14709926.1T patent/ES2691306T3/es active Active
- 2014-03-12 CA CA2899712A patent/CA2899712C/en active Active
- 2014-03-12 JP JP2015562104A patent/JP6453781B2/ja active Active
- 2014-03-12 CN CN201810088883.4A patent/CN108130373A/zh active Pending
- 2014-03-12 US US14/205,751 patent/US20140272961A1/en not_active Abandoned
-
2016
- 2016-02-05 US US15/017,179 patent/US20160160297A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5531367B2 (ja) | 標的配列の濃縮 | |
| US8901285B2 (en) | Polynucleotide primers | |
| JP6968894B2 (ja) | メチル化ｄｎａの多重検出方法 | |
| JP6619332B2 (ja) | ヒトｅｚｈ２遺伝子中の変異を検出するための方法及び組成物 | |
| JP2016510982A5 (enExample) | ||
| US20120288863A1 (en) | Oligonucleotides and methods for detecting KRAS and PIK3CA mutations | |
| JP2014500028A (ja) | ヒト上皮成長因子受容体遺伝子内の突然変異を検出するための方法及び組成物 | |
| JP6453781B2 (ja) | ヒトｐｉ３ｋｃａ（ｐｉｋ３ｃａ）遺伝子変異検出のための方法及び組成物 | |
| WO2017201276A1 (en) | Methods of detecting a mutated gene by multiplex digital pcr | |
| CN105745335A (zh) | 用于对cMET核酸进行多模态分析的组合物及方法 | |
| US20230046513A1 (en) | Pcr method and pcr kit for increasing allelic discrimination | |
| JP2008199965A (ja) | ａｂｌ遺伝子変異の検出用プローブおよびその用途 | |
| JP2016527899A (ja) | Ｎｒａｓ核酸およびｂｒａｆ核酸のマルチプレックス解析のための組成物および方法 | |
| DK2744913T3 (en) | PROGNOSTIC METHODOLOGY | |
| MX2015003386A (es) | Metodo para la deteccion de mutaciones de braf y pi3k. | |
| JP6153758B2 (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| US10724104B2 (en) | Prognostic mean telomere length | |
| JP2008148612A (ja) | 鶏の品種識別のためのツールおよびその利用 | |
| JP6205216B2 (ja) | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット | |
| Zhang et al. | Hairpin amplicon cleavage PCR (HAC-PCR): A novel, highly sensitive and cost-effective approach for detection of low-frequency DNA mutations | |
| WO2016103727A1 (ja) | 特異的核酸配列の増幅促進方法 | |
| JP5570657B2 (ja) | 遺伝子存在量の測定方法 | |
| JP5917248B2 (ja) | ＨＧＦ遺伝子のｐｏｌｙＡｒｅｐｅａｔ数変異多型検出用プローブおよびその用途 | |
| JP2018088883A (ja) | 上皮成長因子受容体遺伝子変異の検出方法 | |
| KR20230037111A (ko) | 대사증후군 특이적 후성유전 메틸화 마커 및 이의 용도 |